COST Action CA18218

2nd International burden of disease conference

Date & Place

14-15 March 2024
The Chamber of Commerce, Piazza della Borsa, 14, Trieste, Italy (https://maps.app.goo.gl/StejJ2Do8WfZEXv36)
Online participation will not be possible


Call for abstracts

The call for abstracts is now closed. Results will be announced on 31 January 2024. Accepted abstracts will be published as a Supplement to Archives of Public Health.

Invited speakers

Emmanuela Gakidou
Prof Dr Emmanuela Gakidou, Institute for Health Metrics and Evaluation (IHME)

Dr Emmanuela Gakidou, co-founder of IHME, holds the positions of Associate Chair for Academic Programs and Senior Director of Organizational Development and Training. Leading two research teams, she focuses on gender disparities and pathways to equality, as well as producing estimates for various health factors. With over 20 years of research experience, her notable work includes gender-based violence, education indicators, and tobacco- and alcohol-related risk factors. In her role as Senior Director, she oversees academic and professional training, staff development, and fellowship programs. Originally from Greece, Dr. Gakidou earned her degrees – an AB, a Master of International Health Economics, and a PhD in Health Policy, from Harvard University and has a background that includes positions at the Harvard Initiative for Global Health and the World Health Organization.

Mark Nieuwenhuijsen
Prof Dr Mark Nieuwenhuijsen, Barcelona Institute of Global Health (ISGlobal)

Dr Mark J Nieuwenhuijsen is director of the Urban Planning, Environment and Health initiative and the Climate, Air pollution, Nature and Urban Health research program at ISGlobal Barcelona, Spain. He is a world leading expert in environmental exposure assessment, epidemiology, and health impact assessment with a strong focus and interest on healthy urban living. He has edited 8 books on Environmental Exposure assessment and Epidemiology, and urban and transport planning and health, co-authored 39 book chapters, and has co-authored more than 500 papers published in peer reviewed journals. In 2018, he was awarded the ISEE John Goldsmith Award for Outstanding Contributions to Environmental Epidemiology. Since 2018 he is among the Clarivate 1% Highly cited scientists in the world. In 2021 he was ranked as the number 1 scientist in Urban health. He leads the bi-annual Urban Transitions conference and he is Editor in Chief of Environment International. In 2020 and 2021 he was the President of the International Society of Environmental Epidemiology. He led 5 large EC funded consortia, including currently UBDPolicy, and is involved many more EC funded research consortia as WP or task leader. He leads the European Urban Burden of Disease project (https://www.isglobal.org/en/-/european-burden-of-disease-project).

Michele Cecchini
Prof Dr Michele Cecchini, Organisation for Economic Co-operation and Development (OECD)

Dr Michele Cecchini is responsible for the OECD programme of work on Public Health including work on preventing unhealthy lifestyles and major risk factors; tackling emerging communicable diseases, with a focus on antimicrobial resistance; and assessing and providing advice on reforms to improve public health systems. His research interests include priority setting and programme evaluation of policies influencing population health, in particular concerning the health and economic assessment of public health policies across different sectors. Michele holds a position of adjunct professor in applied health economics at the School of Public Health of the University of Siena. After obtaining a degree in Medicine and Surgery from the University of Genoa, Michele completed his specialist training in Public Health at the University of Siena. He also obtained a master’s degree in health policy, planning and financing from the London School of Economics and the London School of Hygiene and Tropical Medicine and a PhD from Imperial College London.

Program at a glance

The 2nd International Burden of Disease Conference will cover presentations from our keynote speakers and other burden of disease enthusiasts.

 Thursday 14/03Friday 15/03
9h00 Registration Welcome
  Welcome Keynote lecture Dr Mark Nieuwenhuijsen
10h00 Updates from the European Burden of Disease Network Keynote lecture Dr Michele Cecchini
  Coffee break Coffee break
11h00 Keynote lecture Dr Emmanuela Gakidou
 
Abstract session - Risk factors
 
 
12h00 Lunch break Lunch break
     
13h00    
  Keynote lecture Dr Lorenzo Monasta
Abstract session - Methodology
  
14h00 Abstract session - Burden of disease in Italy
 
15h00 Abstract session - National burden of disease Closure
  Coffee break Coffee break

Detailed program

Thursday 14/03

9h00 Registration
9h30 Welcome
— Dr. Lorenzo Monasta, Italian GBD Initiative & Institute for Maternal and Child Health – IRCCS Burlo Garofolo
— Dr. Massimo Zeviani, Research Director of the Institute for Maternal and Child Health – IRCCS Burlo Garofolo
— Dr. Gianna Zamaro, Director of the Central Regional Directorate for Health, Social Policies and Disability
— Comm. Antonio Paoletti, President of the Chamber of Commerce
10h00 Updates from the European Burden of Disease Network
— Brecht Devleesschauwer, Action Chair, Sciensano, Belgium
10h30 Coffee break
11h00 Keynote lecture
— Emmanuela Gakidou, Institute for Health Metrics and Evaluation
12h00 Lunch
13h30 Keynote lecture
— Lorenzo Monasta, Italian GBD Initiative & Institute for Maternal and Child Health – IRCCS Burlo Garofolo
14h00 Health status and disparities across regions in Italy, 1990-2019: a systematic analysis for the Global Burden of Disease study 2021
— Giulia Zamagni, Institute for Maternal and Child Health – IRCCS Burlo Garofolo, Italy
  Incidence, Prevalence, and Disability Associated with Young-Onset Dementia in Italy (1990-2019): A Global Burden of Disease Study Analysis
— Daniele Urso, University of Bari, Italy
  Fine particles and lung cancer mortality in Tuscany (Italy): A Bayesian health impact assessment
— Michela Baccini, University of Florence, Italy
  Lung cancer and smoking: years lived with disability in Tuscany. An analysis from the ACAB study
— Giulia Carreras, Institute for cancer research, prevention and clinical network (ISPRO), Italy
15h00 Burden of Disease Study at the national and regional level in Germany – updates and perspectives
— Elena von der Lippe, Robert Koch Institute, Germany
  Trends of Gaps between Health-Adjusted Life Expectancy (HALE) and Life Expectancy at the Regional Level in South Korea: using group-based multi-trajectory modeling approach (2008-2019)
— Chung-Nyun Kim, Korea University, Republic of Korea
15h30 Coffee break

Friday 15/03

9h00 Welcome
9h30 Keynote lecture
— Mark Nieuwenhuijsen, ISGlobal
10h00 Keynote lecture
— Michele Cecchini, Organisation for Economic Cooperation and Development
10h30 Coffee break
11h00 Burden attributable to the carbon footprint of the health sector in the European Union
— José Chen-Xu, NOVA National School of Public Health, Portugal
  Expanding standard methodologies for correcting under-reported alcohol use survey data for the establishment of a time series in Belgium, 1997-2020
— Sarah Nayani, Sciensano, Belgium
  Disparities in educational attainment and COVID-19 premature mortality in Serbia
— Aleksandar Stevanović, University of Belgrade, Serbia
12h00 Lunch
13h30 Deriving disability weights: are there differences in health state preferences across population sub-groups?
— Periklis Charalampous, Erasmus Medical Centre, the Netherlands
  Impact of new disability weights on burden of disease estimates for the Netherlands
— Marjanne Plasmans, National Institute for Public Health and the Environment, the Netherlands
  Estimating the Burden of COVID-19 in Luxembourg over three years of pandemic, with a particular focus on the uncertainty associated with post-acute consequences
— Susanne Schmitz, Ministry of Health, Luxembourg
  A Systematic Review of the Methodological Considerations in Campylobacter Burden of Disease Studies
— Megan Tumulty, University College Cork, Ireland
  Burden of selected cancers in Germany – methodology and results
— Alexander Rommel, Robert Koch Institute, Germany
15h00 Closure of the International Burden of Disease Conference
— Milena Šantrić Milićević, Action Vice-Chair, University of Belgrade, Serbia
— Brecht Devleesschauwer, Action Chair, Sciensano, Belgium
15h30 Coffee break

Poster presentations

Assessing the health impact of disasters: the disasters health burden (DHB) project using Disability-Adjusted Life Years
— Margo Tonnelier, Université catholique de Louvain, Belgium
Burden of disease and EU legislation: Is research guiding policymaking?
— José Chen-Xu, NOVA National School of Public Health, Portugal
Burden of Down Syndrome in Romania, 1990-2019: results from the Global Burden of Disease 2019 study
— Diana A. Grad, Babes-Bolyai University, Romania
Changes in burden of anxiety disorders in the Balkan countries
— Jovana Todorovic, University of Belgrade, Serbia
Dietary habits of the Italian population across the last 30 years: main features and room for improvements
— Matteo Perillo, University of Bologna, Italy
Estimation of the environmental burden of disease related to arsenic exposure in European populations
— Rafiqa Benchrih, Sciensano, Belgium
Evaluation of integrated One Health economic policies to control Crimean Congo Hemorrhagic Fever – A case scenario from Bangladesh
— Muhammad Asaduzzaman, University of Oslo, Norway
Gender differences in the burden of hepatitis B and C virus infections in Armenia
— Anahit Demirchyan, American University of Armenia, Armenia
Impact of heatwaves on the burden of cardio-cerebrovascular diseases in Portugal from 2010 to 2018
— Hernan Gómez Redondo, DTU National Food Institute, Denmark
Impact of malignant neoplasms on women's years of life lost in pre and post-pandemic eras in the Federation of Bosnia and Herzegovina
— Šeila Cilović Lagarija, Institute for Public Health FB&H, Bosnia and Herzegovina
Incidence, prevalence, and burden of traumatic brain injury in the European Under-5 population between 1990-2019: A comparative analysis based on the Global Burden of Disease study 2019
— Stefano Giannoni-Luza, University of Bari, Italy
Knowledge translation of burden of disease data for public health policy
— Elena Pallari, German Medical Institute, Cyprus
Morbidity and mortality of dementia in the European Union and its socio-economic correlates: analysis of the GBD 2020 Study
— Giancarlo Logroscino, University of Bari, Italy
Oral cavity cancer: characterization of the Years of Life Lost (YLL) in Portugal
— Carina Ladeira, Escola Superior de Tecnologia da Saúde de Lisboa, Portugal
Premature mortality burden due to sepsis in the Belgrade population during the COVID-19 pandemic
— Natasa Rosic, City Institute of Public Health, Belgrade, Serbia
Prioritization method of risk-outcome pairs to conduct an initial assessment of the environmental burden of disease
— Sabrina Delaunay-Havard, Santé Publique France, France
Quality-adjusted life expectancy: how different from other health expectancies’ methods
— João Vasco Santos, University of Porto, Portugal
The burden of anxiety disorders in Montenegro, 1999-2019: findings from the GBD 2019
— Lidija Scepanovic, Institute of Public Health of Montenegro, Montenegro
The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990−2019: Findings from the Global Burden of Disease Study 2019
— Giulio Castelpietra, Regione Autonoma Friuli Venezia Giulia, Italy
The peripandemic impact of cervical and breast cancer on women's years of life lost in the Federation of Bosnia and Herzegovina
— Šeila Cilović Lagarija, Institute for Public Health FB&H, Bosnia and Herzegovina
The peripandemic impact of colorectal malignant neoplasms on years of life lost in the Federation of Bosnia and Herzegovina
— Siniša Skočibušić, Institute for Public Health FB&H, Bosnia and Herzegovina
Towards Healthy Ageing: Assessing the Impact of Healthcare Access, Quality, and Universal Coverage in Europe and the United Kingdom in 2019
— Brian Curtin, University College Cork, Ireland

Reimbursement

Attendance to the conference is free of charge. The European Burden of Disease Network is able to reimburse travel and accomodation of up to 50 network members. Reimbursement will cover long-distance travel (up to 1500 EUR) and a per diem flat rate of 120 EUR per day, for a maximum of 3 days. Detailed reimbursement rules are available via https://www.cost.eu/travel_reimbursement_rules and the COST Annotated Rules.

How to obtain your reimbursement

  • You will only be able to submit your reimbursement claim after the event
  • You will be able to encode your reimbursement via the invitation link provided to you by e-mail and available in e-COST
  • Attendance will be verified based on the attendance list; during the event, you should therefore sign the Attendance List on each day that you are attending the conference
  • The deadline to submit your reimbursement claim online is 15 days after the event via your invitation link
  • Please ensure that you register in e-COST the same e-mail address as in your invitation and that your bank details are up to date

If you are unsure whether you are eligible to receive reimbursement, please check your e-COST invitation, or contact .

Registration

Participation to the conference is free of charge, but registration is required.

Click here to register before 29 February 2024

About COST

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. COST Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. Read more via cost.eu.

Get in touch

COST logo

Funded by the European Union

Website by  woluweb mini